(Total Views: 631)
Posted On: 08/22/2021 9:56:02 PM
Post# of 153974
Daltondog,
I believe you are correct.
The mTNBC 1b/2 trial is slated to end in March 2022, with the results reported in July an interim analysis.
More than half of the 30 enrolled patients must remain alive if they are unable yet to calculate median overall survival (mOS).
I was very happy to read the analysis from Creatv Microtech, as we had not heard from them in a year.
The exciting quote:
Daniel Adams, Director of Clinical Research & Development, Creatv MicroTech, Inc., stated, “While these are only interim results at the12-month point, our ability to rapidly monitor and identify patients that appear to respond to leronlimab using a single tube of blood is quite an encouraging finding. The fact that greater than 70% of patients saw positive changes in circulating tumor cells after a single dose of leronlimab was made even more informative by their dramatic increases in both progression-free survival and overall survival. The fact that a large group of patients taking leronlimab had an mPFS of approximately 6 months is well beyond that experienced with current treatment options available to these women, who typically have mPFS of approximately 2 months. This result is even more amazing as these women did not even reach mOS in 12 months, considering the typical mOS in this population is only 6 to 7 months.”
https://www.cytodyn.com/investors/sec-filings...221967.pdf
I believe you are correct.
Quote:
Didn't they say that they had not even reach mOS at 12 months
The mTNBC 1b/2 trial is slated to end in March 2022, with the results reported in July an interim analysis.
More than half of the 30 enrolled patients must remain alive if they are unable yet to calculate median overall survival (mOS).
I was very happy to read the analysis from Creatv Microtech, as we had not heard from them in a year.
The exciting quote:
Daniel Adams, Director of Clinical Research & Development, Creatv MicroTech, Inc., stated, “While these are only interim results at the12-month point, our ability to rapidly monitor and identify patients that appear to respond to leronlimab using a single tube of blood is quite an encouraging finding. The fact that greater than 70% of patients saw positive changes in circulating tumor cells after a single dose of leronlimab was made even more informative by their dramatic increases in both progression-free survival and overall survival. The fact that a large group of patients taking leronlimab had an mPFS of approximately 6 months is well beyond that experienced with current treatment options available to these women, who typically have mPFS of approximately 2 months. This result is even more amazing as these women did not even reach mOS in 12 months, considering the typical mOS in this population is only 6 to 7 months.”
https://www.cytodyn.com/investors/sec-filings...221967.pdf
(8)
(0)
